Of the 5,015 distinct dietary ingredients cataloged in the federal government's Dietary Supplement Label Database, 1,519 — 30.3 percent — appear on the label of exactly one brand. Meanwhile the top of the list looks nothing like a health-food aisle: the single most common "ingredient" across 192,026 supplement products is Calories, followed by Calcium, Carbohydrate, Vitamin C, and Sugar. Real botanicals barely crack the top ranks at all. This is what an unregulated-at-entry market leaves as a fingerprint: a dense core of nutrition-panel boilerplate and a long, thin tail of one-off exotica.
What the data shows
We queried the public Dietary Supplement Label Database (DSLD), maintained by NIH's Office of Dietary Supplements from FDA-regulated product labels — 5,015 ingredient records, 5,487 brands, 192,026 products. Botanicals are the largest single ingredient category at 2,177 records (43.4%), more than double the next category ("non-nutrient/non-botanical," 1,268, 25.3%). But scale by category doesn't mean scale by usage: of those 2,177 botanicals, 656 (30.1%) are tied to just one brand each — things like Persicaria lapathifolia, Typhonium flagelliforme, and "Missouri Snakeroot," each sitting in a handful of products from a single manufacturer. Across the whole ingredient set, 2,555 ingredients (51.0%) appear in three brands or fewer.
Why the market looks like this
The mechanism is DSHEA — the Dietary Supplement Health and Education Act of 1994. Under DSHEA, FDA has no premarket approval authority over dietary ingredients; a firm doesn't need agency sign-off on safety or efficacy before selling a product. The only gate is the New Dietary Ingredient (NDI) notification: if an ingredient wasn't marketed before October 15, 1994, the company must notify FDA at least 75 days before launch with evidence the ingredient is "reasonably expected to be safe" — and if it skips that step, the product is legally adulterated regardless of what happens after (FDA NDI background). That low, self-certifying bar is exactly what produces this shape of data: it's cheap for a small manufacturer to formulate around one obscure plant extract and launch under its own name, because there's no regulatory review cost to clear first — only a paperwork step that enforcement resources can't fully police. FDA's own 2025 warning letter to Blue Forest Farms over Amanita muscaria and its psychoactive constituents (ibotenic acid, muscarine, muscimol) illustrates the failure mode: the agency found "inadequate information to provide reasonable assurance of safety" only *after* the product was already on shelves (FDA warning letter, 9/11/2025).
Caveats
DSLD is a voluntary label-image database, not a sales or safety registry — a brand's presence doesn't confirm the product is still sold, and "total_brands" reflects how many labels have been indexed, not market share or unit volume. Ingredient names aren't fully deduplicated across synonyms, which can inflate apparent fragmentation at the margins. And the count of single-brand botanicals says nothing about which of them are actually unsafe — most are simply rare, legitimate, or old ethnobotanical ingredients that happen to have thin distribution.
Why this matters
A catalog where half the ingredient list has almost no distribution, and the widest-used entries are generic nutrition-facts fields rather than differentiated actives, is a structural signature of pre-market self-certification, not evidence of a defect in the data. For anyone doing supply-chain, competitive, or compliance diligence on this sector, ingredient-level DSLD data is a leading indicator worth monitoring directly — NDI gaps tend to surface in a handful of low-distribution SKUs long before they show up in an FDA enforcement action.